Merestinib Recruiting Phase 1 Trials for Relapsed Adult Acute Myeloid Leukemia / Refractory Adult Acute Myeloid Leukemia Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03125239Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia